Group 1 - Heptares Therapeutics has entered into a licensing and equity cooperation agreement with Solstice Oncology for HBM4003, granting exclusive rights for development and commercialization outside Greater China, with potential upfront payments exceeding $105 million [1] - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, one of which is in the IND stage, marking a significant breakthrough in its international strategy [2] - CStone Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency for a new indication of Sugli monoclonal antibody for treating adult patients with advanced non-small cell lung cancer, highlighting its global operational capabilities [3] Group 2 - Novo Nordisk's stock has dropped significantly following the disappointing clinical data for CagriSema, which showed only a 23% weight loss effect, failing to meet the primary endpoint of the trial [4] - Tongce Medical's chairman and executives have announced plans to increase their shareholding in the company, aiming to stabilize market sentiment amid pressures from weak consumer demand and dental implant procurement [5]

丨2026年2月24日星期二丨 NO.1 和铂医药就新一代CTLA-4抗体达成授权协议及股权合作 2月23日，和铂医药公告称，公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协 议。据此，公司同意向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶 段组合资产HBM4003。根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价。 2月23日，基石药业公告称，舒格利单抗的新适应证申请已获英国药品和医疗保健用品管理局批准单药 用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因子受体敏感突变或ALK、ROS1基因组变异、在含铂 放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌成人患者。 点评：这是舒格利单抗出海进程的又一里程碑。不过，非小细胞肺癌领域PD-1/PD-L1竞争白热化，基 石药业需依托合作伙伴的本地化商业化能力抢占份额，本次获批更多体现监管认可度与全球化运营能力 的提升。 NO.4 诺和诺德股价大跌，CagriSema临床数据不及预期 2月23日，丹麦药企诺和诺德股价大跌。消息面上，公司公布了CagriSema临床 ...

Core Viewpoint - Novo Nordisk (NVO.US) experienced a significant drop of nearly 16%, trading at $39.97, while Eli Lilly (LLY.US) saw an increase of over 4%, trading at $1055.47. This market reaction follows Novo Nordisk's announcement that its weight loss drug Cagrisema showed less effective results compared to Eli Lilly's Zepbound [1]. Company Summary - Novo Nordisk's Cagrisema drug trial results were disappointing, leading to a sharp decline in its stock price [1]. - Eli Lilly's Zepbound demonstrated superior efficacy in comparison to Cagrisema, contributing to Eli Lilly's stock price increase [1].

每经记者｜郑雨航 每经编辑｜何小桃 兰素英 ①【美国关税政策不确定性笼罩市场，三大期指走低】道指期货跌0.29%、标普500指数期货跌0.30%、纳指期货跌0.33%。 消息面上，美国最高法院2月20日裁决美国政府征收大规模关税政策"越权"后，美总统特朗普立即祭出新的行政令，宣布自2026年2月24日起，对来自所有 国家和地区的商品加征10%的进口关税。21日，特朗普又宣布，把这项新征收的"全球进口关税"税率由10%提升至15%。贸易政策缺乏明确性可能导致全 球前景蒙上阴影，并使各市场波动性维持高位。 ②【热门中概股普涨】中概股盘前普涨。拼多多、蔚来汽车涨近2%，京东、阿里巴巴涨超1%，百度涨超0.5%。 ③【加密货币概念股走低】比特币日内一度跌破6.5万美元，加密货币概念股盘前走低。Strategy、MARA Holdings、Terawulf跌超2%，Coinbase Global跌 近2%。 ④【芯片半导体股走低】芯片半导体板块盘前走低。台积电、阿斯麦跌超1%，美光科技跌近1%，英伟达微跌。 记者|郑雨航 编辑|何小桃 兰素英 杜恒峰 校对|魏文艺 ⑥【加州州长：美国总统正摧毁美国经济】据央视新闻，在当 ...

Core Viewpoint - Novo Nordisk has received FDA approval for its oral weight loss drug Wegovy, set to launch in January 2026 at a starting price of $149 per month, potentially making it more accessible than its injectable counterpart [5][14]. Group 1: Novo Nordisk's Product Launch - The oral version of Wegovy is designed to provide weight loss results comparable to the injectable version, with the added convenience of daily oral administration [5]. - The active ingredient in the oral drug is semaglutide, the same as in the injectable Wegovy and Ozempic, but with a higher dosage in the new formulation [5]. - Novo Nordisk has reached an agreement with Trump to allow self-paying patients to purchase the drug at the same price through a new website launching in January [5]. Group 2: Competitive Landscape - Eli Lilly, a major competitor, is also developing an oral weight loss drug and has submitted it for FDA approval, which is expected to follow shortly after Novo Nordisk's approval [7]. - Eli Lilly's injectable weight loss drugs use tirzepatide, while its oral formulation is based on a new ingredient, orforglipron [7]. - Recent performance shows Eli Lilly's Zepbound has surpassed Novo Nordisk's Wegovy in revenue contribution [8]. Group 3: Drug Efficacy and Development - Novo Nordisk's oral drug includes a protective component, SNAC, to prevent rapid degradation in the stomach, requiring patients to take it on an empty stomach [11]. - Clinical studies indicate that Novo Nordisk's oral formulation achieves weight loss comparable to its injectable version over 64 weeks, while Eli Lilly's oral drug shows less efficacy compared to its injectable [11]. - Both companies are exploring next-generation drugs, with Novo Nordisk researching cagrilintide and Eli Lilly focusing on retatrutide, which may offer enhanced weight loss and metabolic benefits [12]. Group 4: Market Impact and Stock Performance - Following the approval of the oral weight loss drug, Novo Nordisk's stock rose by 7.30%, reaching a market capitalization of $175 billion, although it has seen a year-to-date decline of 38.35% [14]. - Eli Lilly's stock has increased by 39.54% year-to-date, reflecting strong market confidence in its weight loss products [14]. - Pfizer has entered the weight loss drug market by acquiring Metsera for approximately $100 billion, aiming to develop a monthly injectable GLP-1 receptor agonist [13][14].

Core Viewpoint - The innovative drug sector has emerged as one of the brightest segments in the Hong Kong stock market this year, with significant recognition from international capital reflected in the performance of the Hong Kong innovative drug ETF, which has seen a year-to-date increase of over 100% and a maximum increase exceeding 130% [3][4]. Group 1: Market Performance and Investor Dynamics - The Hong Kong stock market, primarily driven by institutional investors, has benefited from deep international capital participation, enhancing pricing efficiency and aligning stock prices closer to intrinsic values [4]. - The continuous inflow of southbound funds has strengthened the correlation between Hong Kong and A-share markets, providing important value references for A-shares [4]. - Notable companies like 恒瑞医药 (Hengrui Medicine) and 宁德时代 (CATL) have seen their H-shares trading at significantly higher prices than their A-shares, indicating a willingness in the Hong Kong market to pay higher valuation premiums for quality enterprises [5]. Group 2: Company-Specific Developments - 博瑞医药 (Borui Medicine) has announced plans to issue H-shares and list on the Hong Kong Stock Exchange, marking a step towards deeper engagement with international capital [5][6]. - The anticipated use of funds from the H-share issuance is likely focused on drug research and development, particularly for the GLP-1 series innovative drugs, with significant ongoing clinical trials [6][7]. - In the first half of the year, 博瑞医药's R&D investment reached 348 million, a year-on-year increase of 144.07%, representing approximately 65% of its total revenue for that period [7][10]. Group 3: R&D Strategy and Pipeline - 博瑞医药's current pipeline includes several innovative drugs targeting weight loss and diabetes, with the BGM0504 injection having entered Phase III clinical trials [6][21]. - The company is actively pursuing an integrated strategy for raw materials and formulations, necessitating substantial capital investment to maintain its competitive edge in GLP-1 research and development [13][24]. - The R&D intensity of 博瑞医药 is comparable to many innovative pharmaceutical companies that have not yet commercialized their products, indicating a strong focus on future growth despite current financial pressures [8][11]. Group 4: Competitive Landscape - 博瑞医药's product matrix is strategically designed to address different patient demographics, with specific formulations targeting both low and high weight loss needs [21]. - The company aims to differentiate itself in the competitive GLP-1 market by developing unique formulations and leveraging advanced technologies for oral drug delivery, which could significantly enhance patient compliance and treatment outcomes [22][23]. - Clinical data from 博瑞医药's BGM0504 injection shows promising results, with a weight reduction of 18.5% and a significant percentage of patients achieving substantial weight loss [22].

Group 1 - Novo Nordisk plans to apply for U.S. regulatory approval for a high-dose version of its weight loss therapy "Wegovy," aiming to compete against Eli Lilly's Zepbound in the growing obesity treatment market [1] - The company's Chief Scientific Officer, Martin Holst Lange, stated that the high-dose Wegovy has comparable weight loss potential to Eli Lilly's offering, providing new treatment options for patients [1] - Novo Nordisk is building a diversified product portfolio around the active ingredient semaglutide, which includes both high-dose injections and an oral tablet version of Wegovy [1] Group 2 - Earlier this year, Novo Nordisk submitted an application for the high-dose Wegovy in Europe [2] - The company reiterated plans to conduct late-stage clinical trials for the experimental compound cagrilintide, which operates through a different mechanism than semaglutide [2] - Novo Nordisk is adjusting its R&D strategy following underwhelming results from its next-generation obesity therapy CagriSema, planning to test cagrilintide's efficacy separately and optimize CagriSema's positioning through new clinical trials [2]

Investment Rating - The report maintains an investment rating of "Leading the Market" for the chemical pharmaceutical industry, indicating an expected price increase exceeding the benchmark index by over 10% [9]. Core Insights - The GLP-1 and Amylin combination therapy has shown significant potential in weight loss for overweight and obese patients, with clinical trials demonstrating superior results compared to existing treatments [3][4]. - The CagriSema combination of GLP-1 RA and Amylin has achieved major clinical endpoints in Phase III trials, with a weight reduction of -22.7% over 68 weeks, outperforming individual components [4]. - The Amycretin dual agonist has also shown promising results in early clinical trials, with weight reductions of -24.3% and -13.1% in different dosing regimens [5]. Summary by Sections Market Performance - The chemical pharmaceutical industry has experienced rapid growth, particularly in the sales of PDE 3/4 inhibitors for COPD maintenance therapy, with ongoing clinical advancements in related conditions [3]. Drug Evaluation - The report highlights the efficacy and safety of BGB-43395 in breast cancer and solid tumor patients, indicating initial positive outcomes [3]. Clinical Trial Results - In the REDEFINE 1 trial, CagriSema demonstrated a weight loss of -22.7% in non-diabetic obese patients, with 34.7% of participants losing ≥25% of their body weight [4]. - In the REDEFINE 2 trial, diabetic obese patients treated with CagriSema achieved a weight loss of -15.7%, with 22.9% losing ≥20% [4]. Preclinical Findings - The combination of BGM0504 and BGM1812 showed superior weight loss effects in diet-induced obesity models, indicating the potential for further development of GLP-1/GIP RA and Amylin combination therapies [6].

Core Viewpoint - Semaglutide, developed by Novo Nordisk, has significantly impacted the weight loss market with over $7.8 billion in global sales in Q1 this year, approved for treating type 2 diabetes and obesity [2] - Tirzepatide, developed by Eli Lilly, is rapidly gaining ground, showing superior weight loss results compared to Semaglutide in recent studies [4][5] Group 1: Clinical Trial Results - In the SURMOUNT-5 trial, Tirzepatide led to an average weight loss of 20.2% (approximately 22.8 kg) over 72 weeks, with 31.6% of participants losing 25% or more of their body weight [5] - The REDEFINE 1 trial showed that the combination of Cagrilintide and Semaglutide (CagriSema) resulted in an average weight loss of 20.4% (approximately 26.6 kg) over 68 weeks, outperforming both Semaglutide and Cagrilintide alone [8] - In the REDEFINE 2 trial, CagriSema achieved an average weight loss of 13.7% in type 2 diabetes patients, significantly higher than the 3.4% in the placebo group [10][13] Group 2: Safety and Side Effects - CagriSema treatment was associated with a higher incidence of gastrointestinal adverse events (79.6%) compared to the placebo group (39.9%), though most symptoms were mild to moderate [8][13] - In the REDEFINE 2 trial, 72.5% of CagriSema participants reported gastrointestinal side effects, again higher than the 34.4% in the placebo group [13] Group 3: Market Outlook - The combination of Semaglutide and Cagrilintide shows potential to become a significant player in the obesity treatment market, alongside Semaglutide and Tirzepatide [14] - The results from recent clinical trials suggest that CagriSema may redefine the competitive landscape of weight loss medications, particularly in both diabetic and non-diabetic populations [14]

Core Viewpoint - Semaglutide, developed by Novo Nordisk, is a GLP-1 receptor agonist that suppresses appetite and reduces caloric intake, approved for treating type 2 diabetes and weight loss. Its emergence has disrupted the weight loss drug market, with sales exceeding $7.8 billion in Q1 this year. However, Eli Lilly's Tizepatide has surpassed Semaglutide's weight loss records, achieving an average weight reduction of 20.2% in a head-to-head clinical trial [2][3]. Group 1: Sales and Market Impact - Tizepatide's sales in Q1 have already exceeded $6.1 billion, narrowing the gap with Semaglutide [3]. - The clinical trial results published in NEJM indicate that Tizepatide outperforms Semaglutide in weight loss effectiveness [2][3]. Group 2: Clinical Trials and Results - The REDEFINE 1 trial showed that the combination of Cagrilintide and Semaglutide resulted in an average weight loss of 20.4% over 68 weeks among non-diabetic overweight/obese participants, with 34.7% losing ≥25% of their body weight [11][13]. - In the REDEFINE 2 trial, the same combination led to a 13.7% average weight loss in overweight/obese participants with type 2 diabetes, significantly higher than the placebo group [17][19]. Group 3: Health Benefits and Safety - Cagrilintide and Semaglutide combination therapy showed improvements in various health metrics, including a 9.9 mmHg reduction in systolic blood pressure compared to 3.2 mmHg in the placebo group [13]. - The incidence of gastrointestinal adverse events was higher in the combination therapy group (79.6%) compared to the placebo group (39.9%), but most events were transient and mild to moderate in severity [14][20].